Breaks Categories: Stock Spotlights

TuesdayJan 10, 2017 1:25 pm

NetworkNewsBreaks – Pluristem (NASDAQ: PSTI) Receives FDA Clearance for Phase 3 PLX-PAD Cells Study; Shares Higher

Shares of Pluristem Therapeutics (NASDAQ: PSTI) are up 7% mid-morning following news that the FDA has cleared the company’s phase 3 study of its PLX-PAD cells in the treatment of critical limb ischemia (CLI). Patients with CLI are at an immediate risk for limb amputation and death, and with meager treatment options, have a severe unmet medical need. The company said it intends to use the results of its study to submit a biologics license application to the FDA for marketing approval. The study is expected to begin patient enrollment in both the U.S. and Europe by June 2017.  “We…

Continue Reading

FridayJan 06, 2017 1:39 pm

NetworkNewsBreaks – Identiv, Inc. (NASDAQ: INVE), NXP Semiconductors (NASDAQ: NXPI) Partner to Provide Smart Badges for CES 2017

Identiv (NASDAQ: INVE), a provider of radio frequency ID (RFID) inlays, has partnered with NXP Semiconductors N.V. (NASDAQ: NXPI) to provide RFID-inlayed badges to the 170,000+ attendees of the ongoing CES 2017 tradeshow in Las Vegas. Identiv’s high-end high-quality inlay is designed exclusively for NXP’s MIFARE DESFire EV2 state-of-the-art platform. The combined technologies enable CES attendees to quickly and securely share contact details, as well as use their badge to get into events, ride the Las Vegas Monorail, and access bike-sharing services. “Together with NXP, we are bringing fast, reliable, and safe access and transportation to all attendees during the…

Continue Reading

ThursdayJan 05, 2017 1:45 pm

NetworkNewsBreaks – Cytori (NASDAQ: CYTX) Continues to Advance Cytori Cell Therapy Clinical Trial

Cytori Therapeutics (NASDAQ: CYTX) continues to move forward with its Cytori Cell Therapy™ program, and in mid-December enrolled and treated more than half of the 45 patients in its ADRESU trial in Japan to study the efficacy and safety of Cytori Cell Therapy™ in men with stress urinary incontinence after prostatic intervention for prostate cancer or benign prostatic hypertrophy. Cytori Cell Therapy™ is being developed as a therapy to be delivered in a single treatment, designed to avoid the need for frequent re-treatment. The company reports that the therapy has thus far been well-tolerated and that it expects full enrollment…

Continue Reading

ThursdayJan 05, 2017 1:43 pm

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Optimistic as U.S. Housing Hits Record High of $29.6T

Investor confidence in the real estate industry was strong in 2016, evidenced by Zillow research (http://nnw.fm/Qyi23) that shows the value of U.S. housing stock increased to a record $29.6 trillion for the year, up nearly 6% over 2015. Though rising interest rates are likely to yield an unfavorable impact for homebuyers in 2017, eXp World Holdings (OTCQB: EXPI) remains optimistic about its own performance amid the changes. “Most recently, RISMedia (http://nnw.fm/l7zcS) published a study highlighting the fact that more real estate executives are confident about their own local economies than about the world economy. Yet many real estate executives are…

Continue Reading

ThursdayJan 05, 2017 10:45 am

NetworkNewsBreaks – How Caladrius Biosciences, Inc. (NASDAQ: CLBS) is Tackling Type 1 Diabetes Mellitus

Autoimmune diseases cost the U.S. more than $100 million annually. Immune tolerance happens, among other things, from the suppression of self-reactive T effector cells and auto-antigen presenting cells by T-regulatory (Treg) cells. A deficit of T-regulatory cells can lead to serious allergic and autoimmune diseases, such as Type 1 diabetes mellitus (T1DM). Caladrius Biosciences (NASDAQ: CLBS) uses T Regulatory Cell Technology to increase autologous T-regulatory cells and function, representing the potential for "true disease modification." The company is developing a therapy based on this technology (CLBS03) for the treatment of T1DM. After announcing positive results for a phase 1 study…

Continue Reading

WednesdayJan 04, 2017 12:25 pm

NetworkNewsBreaks – Finjan Holdings, Inc. (NASDAQ: FNJN) Shares Continue Rally on Licensing Agreement, Record Revenues of $18M

Shares of cybersecurity provider Finjan Holdings (NASDAQ: FNJN) are up 9%, continuing a rally on yesterday’s news that the company’s Finjan, Inc. subsidiary is closing a Confidential Patent License Agreement with F5 Networks, Inc. The company also reported record revenues stemming from initiatives to lower costs and maximize efficiencies. "The F5 license agreement is meaningful as it is the first under our enhanced licensing program initiated to streamline efforts, reduce costs and improve efficiencies. As a result of our enforcement efforts we closed a record year at Finjan with more than $18 million in revenue, an almost four-fold increase over…

Continue Reading

WednesdayJan 04, 2017 12:22 pm

NetworkNewsBreaks – Inventergy Global, Inc. (NASDAQ: INVT) Kicks-off Patent Licensing Campaign for GTX Corp (GTXO) Technology

IP licensing and innovation company Inventergy Global (NASDAQ: INVT) this morning said its subsidiary, Inventergy Innovations, LLC,  has launched a patent licensing campaign for GTX Corp (OTC: GTXO) for its wireless location-based services IP assets based on two-way GPS tracking. As a follow-up to a definitive agreement announced in June 2016, the licensing campaign will provide substantial discounts for early adoption, multi-year commitments or higher volumes of products to companies interested in the Comm. Protocol family. "In our Inventergy Innovations model we obtain exclusive rights to license or sell a partner's patents, technology or in some cases their entire company. We use…

Continue Reading

WednesdayJan 04, 2017 12:18 pm

NetworkNewsBreaks – Bellerophon Therapeutics, Inc. (NASDAQ: BLPH): FDA Approves Protocol Changes for Phase 3 INOpulse Program, Shares Tick Higher

Bellerophon Therapeutics (NASDAQ: BLPH) this morning said the U.S. FDA has approved proposed modifications to the company’s phase 3 program for INOpulse in Pulmonary Arterial Hypertension (PAH). The protocol changes have the potential to reduce the time to market and are expected to result in “substantial” costs savings. “We are gratified that the FDA has agreed with the proposed modifications to our PAH Phase 3 program, which have the potential to make INOpulse available to PAH patients approximately two years earlier than otherwise would have been possible under the original Phase 3 program,” Bellerophon president and CEO Fabian Tenenbaum stated…

Continue Reading

TuesdayJan 03, 2017 1:17 pm

NetworkNewsBreaks – Bridgeline Digital, Inc.’s (NASDAQ: BLIN) iAPPS Product Suite Helps Businesses Enhance Digital Assets

Today’s companies increasingly rely on the effectiveness of digital assets for a variety of business functions. Websites, mobile applications and online stores, for example, are now the most powerful marketing tools available. Focusing on digital values, Bridgeline Digital (NASDAQ: BLIN) offers interactive technology solutions designed to enhance a company's web properties. Its iAPPS product suite is a digital engagement platform that incorporates everything from web content management and eCommerce to digital marketing and web analytics. Recently, the iAPPS product suite was chosen by one of the world’s largest engine manufacturers to power its eCommerce website. It allows the company to…

Continue Reading

TuesdayJan 03, 2017 1:11 pm

NetworkNewsBreaks – Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Obtains Orphan Drug Designation for Fragile X Syndrome Treatment

Marinus Pharmaceuticals (NASDAQ: MRNS) this morning said that the FDA has granted Orphan Drug Designation to the company’s CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome, the most common genetic cause of autism, which is caused by a mutation in the FMR1 gene. This designation provides Marinus with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act filing fees. “We are pleased to receive Orphan Drug Designation from the…

Continue Reading